Lyra Therapeutics (LYRA) Tops Q3 EPS by 4c

Lyra Therapeutics (NASDAQ: LYRA) reported Q3 EPS of ($0.18), $0.04 better than the analyst estimate of ($0.22). Revenue for the quarter came in at $195 thousand versus the consensus estimate of $315.6 thousand.

For earnings history and earnings-related data on Lyra Therapeutics (LYRA) click here.

You May Also Be Interested In

• Movano (MOVE) Misses Q2 EPS by 195c
• HeartCore Enterprises, Inc. (HTCR) Misses Q2 EPS by 185c
• Jane Street Took $15 Billion Hit In July Tied To Situational Awareness - Reuters